LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Hutchison China MediTech Ltd ADR

Geschlossen

BrancheGesundheitswesen

15.29 1.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.65

Max

15.38

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.9M

6M

Verkäufe

9.4M

162M

KGV

Branchendurchschnitt

68

51.198

Gewinnspanne

3.676

Angestellte

1,811

EBITDA

5.6M

-5M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+36.63% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-302M

2.4B

Vorheriger Eröffnungskurs

14.17

Vorheriger Schlusskurs

15.29

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Juni 2025, 14:31 UTC

Ergebnisse

New York State Retirement Fund Posts 5.84% Annual Investment Return

6. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Juni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Juni 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6. Juni 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6. Juni 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6. Juni 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6. Juni 2025, 16:35 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 16:34 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. Juni 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Juni 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Juni 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. Juni 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6. Juni 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6. Juni 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6. Juni 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Juni 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6. Juni 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6. Juni 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6. Juni 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Juni 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6. Juni 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6. Juni 2025, 14:12 UTC

Ergebnisse

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6. Juni 2025, 14:09 UTC

Ergebnisse

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Peer-Vergleich

Kursveränderung

Hutchison China MediTech Ltd ADR Prognose

Kursziel

By TipRanks

36.63% Vorteil

12-Monats-Prognose

Durchschnitt 20.85 USD  36.63%

Hoch 27 USD

Tief 14.7 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hutchison China MediTech Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

14.24 / 14.78Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.